Massachusetts health insurers are effectively telling the drug companies that they may seek a rapidly growing customer base ...

CVS Caremark will stop covering Eli Lilly’s Zepbound. Wegovy, the GLP-1 medication to treat obesity from Lilly competitor ...

This is only a glimpse of the data available to CivicScience clients. Discover more data. It’s safe to say that GLP-1 ...

The new arrangement could cut patients' copays to $25 per month, or less, for Wegovy, Zepbound, Ozempic and Rybelsus ...

In a recent panel conversation, healthcare and industry experts discussed where to find reliable guidance in a sea of ...

GLP-1 drugs currently being tested in China target complications associated with obesity such as heart disease, fatty liver ...

Insurers are cutting coverage, citing costs. But there’s seldom any discussion of the return on investment from these drugs ...

New rules are reshaping the telehealth market for GLP-1s like Ozempic and Wegovy, potentially impacting access to these drugs ...

Reduced monthly costs for uninsured patients still amount to around $500. That can put the drugs out of reach for many.

GLP-1 drugs like Ozempic® and Zepbound® have gained significant attention for treating both diabetes and assisting with weight loss.

Pharmacy benefit manager CVS Caremark drops Zepbound coverage, estimating 10-15% savings while Eli Lilly offers self-pay ...

Some online pharmacies sell semaglutide and tirzepatide that are ineffective, unsafe, or an outright scam. Here’s how to find ...